The nanomedicines alliance: an industry perspective on nanomedicines |
| |
| Institution: | 1. Laboratoire de Recherche en Nanosciences (LRN)-EA4682, Université de Reims Champagne-Ardenne, Reims, France;2. Laboratory of Nano-Bioengineering, National Research Nuclear University \"MEPhI\" (Moscow Engineering Physics Institute), Moscow, Russian Federation;3. Inserm U1068, CRCM, Marseille, France;4. Institut Paoli-Calmettes, Marseille, France;5. Aix-Marseille Univ UM105, Marseille, France;6. CNRS UMR7258, CRCM, Marseille, France;1. Swiss Light Source, 5232 Villigen, PSI, Switzerland;2. Australian Synchrotron, Imaging and Medical Beam Line (IMBL), Clayton, Victoria, Australia;3. Beijing Key Lab of Bioprocess, Beijing University of Chemical Technology, Beijing, PR China;4. CSIRO Materials Science and Engineering, Clayton, Victoria, Australia;5. Grenoble Institut des Neurosciences, Grenoble, France;6. Elettra—Sincrotrone Trieste S.C.p.A., Trieste, Italy;7. Istituto Nazionale di Fisica Nucleare-Sezione di Trieste, Trieste, Italy;8. Department of Physics, University of Trieste, Trieste, Italy;9. CSIRO Animal, Food and Health Sciences, Geelong, Victoria, Australia;1. School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia;2. School of Biomedical Sciences, The University of Queensland, St. Lucia, QLD, Australia;3. School of Pharmacy, The University of Queensland, Woollongabba, QLD, Australia |
| |
| Abstract: | The field of nanomedicines has expanded significantly in recent years in the breadth of compounds under development as well as in the types of technology that are being applied to generate nanomedicines. The pathway to licensure of new nanomedicines is sufficiently well defined by existing regulations and guidance. The future of nanomedicines requires collaboration between industry and regulatory agencies to ensure that safe and effective nanomedicines emerge from this field.From the Clinical EditorWith the expansion of translational nanomedicine research, the “last steps” of translation, such as making sure all regulatory approvals are met, the availability of appropriate larger-scale production technologies, are becoming critically important. This review provides a perspective from the biomedical and pharmaceutical industry on the above issues. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
